PML-RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitoring – Molecular Relapse Surveillance, Dubai

Executive Summary & Core Metrics

Clinical Precision Guaranteed: This advanced molecular assay delivers 99.9% diagnostic sensitivity for quantifying minimal residual disease (MRD) in acute promyelocytic leukemia (APL) patients harboring the PML-RARA fusion transcript. Processed via ISO 9001:2015 accredited facility (Cert: INT/EGQ/2509DA/3139) using standardized Real-Time Quantitative PCR (qPCR) methodology with a detection threshold of 10^-4 to 10^-5, ensuring clinically actionable results aligned with DHA Oncology Monitoring Protocols.

Accuracy Guarantee 99.9% Diagnostic Sensitivity (ISO-Accredited qPCR)

Premium Logistics Hospital-Grade Cold-Chain Home Collection | VIP Mobile Phlebotomy

Clinical Guidance Telephonic Post-Test Result Interpretation by Clinical Team

Insurance Verification Direct Billing Confirmation via WhatsApp: +971 54 548 8731

Test Overview & Methodology

The PML-RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitoring test is a high-sensitivity molecular assay designed for serial monitoring of minimal residual disease in patients diagnosed with acute promyelocytic leukemia (APL). This quantitative real-time PCR (qPCR)-based test measures PML-RARA fusion transcript levels in peripheral blood or bone marrow, enabling oncologists and hematologists to assess treatment response, detect early molecular relapse, and guide therapeutic decision-making with sub-microscopic precision long before morphological changes manifest.

In the United Arab Emirates, this quantitative molecular analysis serves as an essential component within DHA oncology protocols for APL surveillance, facilitating early detection of molecular recurrence weeks to months before clinical symptoms emerge.

Feature	Our Test — PML-RARA qPCR MRD	Closest Alternative — Qualitative PCR / FISH
Methodology	Real-Time Quantitative PCR (qPCR) with ISO-Standardized Calibrators	Conventional Qualitative PCR or Fluorescence In Situ Hybridization (FISH)
Analytical Sensitivity	10^-4 to 10^-5 (detects 1 leukemic cell among 10,000–100,000 normal cells)	10^-2 (detects 1 in 100 cells; limited post-remission utility)
Clinical Application	MRD-guided therapy escalation/de-escalation; molecular relapse prediction	Diagnostic confirmation at presentation; insufficient for MRD monitoring
Turnaround Time	24–48 hours (Sample Mon/Wed/Fri by 9 AM; Report Tue/Thu/Sat)	3–7 working days, often outsourced internationally
Sample Requirement	5 mL whole blood OR bone marrow in Lavender Top (EDTA); refrigerated transport	Often requires fresh bone marrow; limited peripheral blood utility
Price	700 AED (Insurance Direct Billing Available)	Variable; often 900–1,500 AED with longer TAT

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor — Specialist Diagnostic Radiology

DHA Registration ID: 61713011 | DNA Labs UAE

"Serial PML-RARA MRD quantification provides the molecular compass that guides clinical decision-making in acute promyelocytic leukemia. The ability to detect a rising transcript burden at a sensitivity of one leukemic cell among 100,000 normal cells transforms surveillance from reactive waiting into proactive intervention. For patients and clinicians alike, these results must always be contextualized within the full clinical narrative — including treatment history, bone marrow morphology, and the patient's own lived experience of their recovery journey."

Critical Medication Advisory

⚠ Do Not Alter Prescribed Therapy

Do not discontinue, modify, or adjust any prescribed medication — including all-trans retinoic acid (ATRA), arsenic trioxide, or any maintenance chemotherapy — without direct consultation with your treating hematologist or oncologist. Abrupt cessation of APL-directed therapy can precipitate life-threatening complications including differentiation syndrome or coagulopathy.

Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria for Sample Collection:

Active, uncontrolled bleeding or disseminated intravascular coagulation (DIC) without prior hematologist clearance
Severe thrombocytopenia (platelet count < 20 × 10⁹/L) without prophylactic platelet transfusion protocol in place
Active cutaneous or soft tissue infection overlying the venipuncture or bone marrow aspiration site
Known anaphylactic allergy to lidocaine or other local anesthetic agents (for bone marrow collection)
Inability to provide informed consent or incomplete MRD Requisition Form (Form 22) with historical molecular data

🚨 Emergency Red Flags — Seek Immediate Medical Attention:

Fever > 38.5°C with or without respiratory distress (potential differentiation syndrome)
Unexplained bruising, petechiae, or mucosal bleeding suggestive of acute coagulopathy
Severe, persistent bone pain unrelated to recent aspiration or biopsy
Acute-onset severe headache, visual changes, or neurological deficit (rule out CNS leukemic involvement)
Rapidly progressive dyspnea, pleuritic chest pain, or signs of pulmonary infiltrates

Patient FAQ & Clinical Guidance

1. What is the clinical importance of quantitative PML-RARA MRD monitoring during and after APL treatment?

Quantitative PML-RARA MRD monitoring provides the most sensitive early-warning system for molecular relapse in acute promyelocytic leukemia, detecting rising leukemic transcript levels months before clinical symptoms or morphological abnormalities appear. Serial qPCR measurements enable your hematologist to track treatment efficacy in real time, distinguish patients who are safely in deep molecular remission from those requiring preemptive therapeutic intervention, and guide decisions on treatment duration — ultimately personalizing your care pathway to maximize long-term survival while minimizing unnecessary treatment toxicity.

2. How should I prepare for the blood or bone marrow sample collection, and are there any special instructions?

For peripheral blood collection, no fasting or special preparation is required; for bone marrow aspiration, your clinical team will provide specific pre-procedure instructions including local anesthetic application and potential light sedation arrangements. Ensure your MRD Requisition Form (Form 22) is completely filled with all historical molecular data, as incomplete documentation is the most common cause of sample rejection. If you are on anticoagulants or antiplatelet medications, inform the collection team in advance. All samples must be transported refrigerated — never frozen — which our ISO-certified cold-chain home collection service manages seamlessly for peripheral blood draws.

3. What does it mean if my MRD result comes back negative, and can I stop treatment?

A negative or undetectable PML-RARA MRD result indicates deep molecular remission, meaning no leukemic fusion transcripts were detected at the test's sensitivity threshold of one cancer cell per ten-to-one-hundred-thousand normal cells. While this is an excellent prognostic finding associated with favorable long-term outcomes, it does NOT independently authorize treatment discontinuation. Your hematologist will integrate this result with your complete clinical picture — including treatment phase, duration of molecular negativity, and current DHA protocol guidelines — before considering any therapy modifications. Continued surveillance testing at regular intervals remains essential even after achieving molecular negativity.

4. How is the sample transported, and what is the turnaround time for results?

Samples must be shipped refrigerated at 2–8°C and reach the laboratory within 24 hours of collection. Our VIP Mobile Phlebotomy service manages temperature-controlled cold-chain logistics for peripheral blood draws directly from your home. Sample acceptance windows are Monday, Wednesday, and Friday by 9:00 AM Gulf Standard Time, with reports issued on Tuesday, Thursday, and Saturday respectively. The standard turnaround time is 24 to 48 hours from sample receipt. Bone marrow aspirates require prior coordination and are collected exclusively within accredited hospital settings.

5. Will my insurance cover the cost of this test, and how do I verify coverage?

The test price is 700 AED, and DNA Labs UAE offers direct insurance billing for most major UAE health insurance plans. To verify your specific coverage, send a WhatsApp message to +971 54 548 8731 with your insurer name and policy number. Our billing team will confirm eligibility, any co-pay requirements, and obtain the necessary pre-authorization before sample collection. Self-pay patients can also proceed directly at the listed price with no additional administrative fees.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Health Information Governance: All patient data, including genomic sequencing results and molecular MRD profiles, are processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks mandate strict confidentiality, purpose-limited data processing, and patient consent protocols for all diagnostic and surveillance testing.

Clinical Safety & Patient Consent: Sample collection, handling, and reporting procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that all invasive procedures — including bone marrow aspiration — are performed only after obtaining written informed consent and under the direct supervision of a qualified medical professional in an accredited healthcare facility.

Accreditation & Certification: ISO 9001:2015 Certified — Certificate No. INT/EGQ/2509DA/3139. All qPCR platforms and calibrators are standardized against international BIOMED-1 and Europe Against Cancer (EAC) MRD harmonization guidelines.

Clinical & Logistical Metadata

Test Name	PML-RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitoring
Price (AED)	700 AED (Insurance Direct Billing Available)
Turnaround Time	24–48 hours (Sample Mon/Wed/Fri by 9 AM; Report Tue/Thu/Sat)
Sample Type / Matrix	5 mL whole blood (Lavender Top EDTA) OR Bone Marrow Aspirate (EDTA). Peripheral blood eligible for VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection. Bone marrow aspiration is a Hospital Extraction Only procedure conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Methodology Used	Real-Time Quantitative PCR (qPCR) with ISO-Standardized Calibrators — bcr1, bcr2, and bcr3 isoform detection capability
ICD-10-CM Code	C92.41 (Acute Promyelocytic Leukemia, in remission), C92.40 (Acute Promyelocytic Leukemia, not having achieved remission), Z85.6 (Personal history of leukemia — MRD surveillance)
LOINC Code	42911-8 — PML/RARA t(15;17) fusion transcript (refer to loinc.org/42911-8)
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE